Cyclin E, with its partner kinase Cdk2, controls cell cycle progression from G1 to S phase. Most human cancers contain mutations in the major pathway that regulates G1 to S phase progression, and these mutations deregulate cyclin E-Cdk2 activity. Though deregulated cyclin E-Cdk2 activity is thought to contribute directly to neoplastic transformation, the mechanisms connecting cyclin E to tumorigenesis remain unclear. We studied the consequences of cyclin E deregulation in primary cells and unexpectedly found that cyclin E overexpression initiates a homeostatic response that restrains cyclin E-Cdk2 activity. When this response is inactivated, overexpressed cyclin E induces profound cell cycle abnormalities and evidence of genetic instability. Therefore, this response, which requires the p53 tumor suppressor protein and the cyclin dependent kinase inhibitor, p21, protects cells against cyclin E deregulation and may comprise a physiologic barrier against cyclin E associated cancer. ? ? The experiments proposed in this application seek to understand the cellular consequences of cyclin E deregulation and the contributions of cyclin E deregulation to tumorigenesis. The goal of Specific Aim 1 is to elucidate the mechanism by which cyclin E activates p53. Excess cyclin E-cdk2 activity induces defective S phase progression and accumulated cytogenetic abnormalities. The goal of Specific Aim 2 is to understand the mechanisms through which cyclin E activity causes genome damage and whether p53 inactivation is an obligatory step in this process. The combination of cyclin E deregulation and p53 loss may be synergistically oncogenic by promoting genetic damage while inactivating the major cellular protective response against this damage. The goal of Specific Aim 3 is thus to determine if cyclin E and p53 loss cooperate during tumorigenesis by developing mouse models of cyclin E associated cancers. ? ? The career development goal of this proposal is to enable the principal investigator to acquire the necessary skills to develop a successful and independent research career with interests bridging cell cycle regulation and tumor biology, This proposal is co-mentored by Drs. Bruce Clurman and James Roberts, who have extensive experience studying cell cycle regulation in normal and cancer cells. The Fred Hutchinson Cancer Research Center includes a thriving community of scientists and physicians with expertise in diverse areas of cancer biology and thus provides an ideal training environment for this research proposal. ? ?
| Minella, Alex C; Loeb, Keith R; Knecht, Andrea et al. (2008) Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev 22:1677-89 |
| Minella, A C; Grim, J E; Welcker, M et al. (2007) p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability. Oncogene 26:6948-53 |
| Minella, Alex C; Welcker, Markus; Clurman, Bruce E (2005) Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci U S A 102:9649-54 |
| Minella, Alex C; Clurman, Bruce E (2005) Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle 4:1356-9 |
| Minella, Alex C; Swanger, Jherek; Bryant, Eileen et al. (2002) p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 12:1817-27 |
